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ABSTRACT
External guide sequences (EGSs), which are RNA
moleculesderivedfromnaturaltRNAs,bindtoatarget
mRNAandrenderthemRNAsusceptibletohydrolysis
by RNase P, a tRNA processing enzyme. Using an
in vitro selection procedure, we have previously gen-
erated EGS variants that efficiently direct human
RNase P to cleave a target mRNA in vitro. In this
study, a variant was used to target the overlapping
region of the mRNAs encoding human cytomega-
lovirus(HCMV)essentialtranscriptionregulatoryfac-
tors IE1 and IE2. The EGS variant was  25-fold more
activeininducinghumanRNasePtocleavethemRNA
in vitro than the EGS derived from a natural tRNA.
Moreover, a reduction of 93% in IE1/IE2 gene expres-
sion and a reduction of 3000-fold in viral growth were
observed in HCMV-infected cells that expressed the
variant, while cells expressing the tRNA-derived
EGS exhibited a reduction of 80% in IE1/IE2 expres-
sion and an inhibition of 150-fold in viral growth. Our
resultsprovide thefirstdirect evidencethatEGSvari-
ant is highly effective in blocking HCMV gene expres-
sion and growth and furthermore, demonstrate the
feasibility of developing effective EGS RNA variants
for anti-HCMVapplications byusing in vitro selection
procedures.
INTRODUCTION
Human cytomegalovirus (HCMV), a ubiquitous herpesvirus,
is an important opportunistic pathogen affecting individuals
whose immune functions are compromised or immature (1,2).
This virus is a leading cause of retinitis-associated blindness
and other debilitating conditions such as pneumonia and enter-
itis among AIDS patients (3,4). Moreover, HCMV causes
mental and behavioral dysfunctions in children that were in-
fected in utero (2). Development of effective antiviral com-
pounds and approaches is crucial in controlling HCMV
infections and preventing HCMV-associated complications.
Nucleicacid-based gene interference technologiesrepresent
promising gene-targeting strategies for speciﬁc inhibition of
mRNA sequences of choice (5,6). For example, ribozymes
have been shown to cleave viral mRNA sequences and inhibit
viral replication in human cells (7–9). More recently, small
interfering RNAs are effective in inducing endogenous RNase
of the RNA-induced silencing complex in the RNA interfer-
ence pathway to inhibit gene expression and growth of several
human viruses (5,10,11). Thus, nucleic acid-based gene inter-
ference approaches can be used as a tool in both basic and
clinical research, such as in studies of tumorogenesis and
antiviral gene therapy.
RNase P is a ribonucleoprotein complex and is responsible
for the 50 maturation of tRNAs (12,13). In Escherichia coli,
this enzyme consists of a catalytic RNA subunit (M1 RNA)
and a protein subunit (C5 protein) (14). It catalyzes a hydro-
lysis reaction to remove a 50 leader sequence from tRNA
precursors (ptRNA). Studies on RNase P substrate recognition
revealed that the enzyme recognizes the structure rather than
the primary nucleotide sequence of the substrates, and can
cleave a model substrate that contains a structure equivalent
to the acceptor stem, the T-stem, the 30 CCA sequence and the
50 leader sequence of a ptRNA molecule (Figure 1A) (13).
Thus, RNase P can cleave an mRNA sequence if the mRNA
substrate forms a hybrid complex with a custom-designed
sequence [external guide sequence (EGS)] to resemble a
ptRNA molecule (Figure 1B–D) (15,16). In this reaction,
the EGS binds to its mRNA substrate through base pairing
interactions and then guides RNase P to cleave the mRNA
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have been shown to be effective in blocking gene expression
in bacteria and in mammalian cells (16–19). We have shown
previously that EGSs that were derived from a natural tRNA
effectively induced human RNase P to cleave the mRNA
of thymidine kinase (TK) of herpes simplex virus 1 (HSV-1)
in vitro (19,20). A reduction of  75% in the expression of
TK mRNA and protein was observed in HSV-1-infected cells
that expressed these functional EGS RNAs.
Targeted cleavage of mRNA by human RNase P provides a
unique approach to inactivate any RNA of known sequence
expressed in vivo. Increasing the in vitro efﬁciency of the
EGS-induced RNase P cleavage as well as its efﬁcacy
in vivo is required in order to develop EGSs for practical
use both as a research tool and as a therapeutic agent for
gene-targeting applications. Using an in vitro selection pro-
cedure, we have recently isolated novel EGS variants that
direct RNase P to cleave TK mRNA in vitro more efﬁciently
than those derived from anatural tRNA sequence (20). Little is
currently known about how these EGS RNA variants increase
their activity in directing RNase P to cleave a target mRNA.
Equally unclear is whether the EGS RNAs are effective in
blocking HCMV gene expression and replication. In this
study, one of these EGS variants was used to target the over-
lapping region of the mRNAs encoding HCMV essential
immediately-early (IE) proteins IE1 and IE2, which are the
viral major transcriptional activators responsible for activation
of viral gene expression (1). We investigated the activityof the
EGS in inducing RNase P to cleave the target mRNA and its
efﬁcacy in inhibiting HCMV gene expression and growth in
cultured cells. The EGS variant, IE-C51, was  25-fold more
active in directing RNase P to cleave the target mRNA than
IE-SER, the EGS derived from a natural tRNA sequence.
When expressed in cultured cells that were infected by
HCMV, IE-C51 was more effective in inhibiting viral gene
expression and growth than IE-SER. A reduction of >93% in
the IE1 and IE2 expression and an inhibition of at least 3000-
fold were observed in cells that expressed IE-C51. In contrast,
a reduction of <10% in viral gene expression and growth was
observed in cells that either did not express an EGS or
expressed EGSs that contained point mutations abolishing
their ability to induce RNase P-mediated cleavage. Our results
provide the ﬁrst direct evidence that engineered EGS RNAs
are highly effective in blocking HCMV gene expression
and growth. These results also demonstrate the potential of
generating highly active EGS variants and using them as a
research tool and as a therapeutic agent for gene-targeting
applications.
MATERIALS AND METHODS
Viruses, cells and antibodies
HCMV (strain AD169) was propagated in human foreskin
ﬁbroblasts and astrocytoma U373MG cells in DMEM supple-
mented with 10% fetal bovine serum (FBS) (Gibco BRL,
Grand Island, NY) as described previously (21,22). The mono-
clonal antibodies c1202, c1203 and c1207, which react
with HCMV proteins UL44, IE1/IE2 and UL99, respectively,
were purchased from Goodwin Institute for Cancer
Research (Plantation, FL). The monoclonal antibodies against
HCMV gH and human actin were purchased from Biodesign
Inc (Kennebunk, Maine) and Sigma Inc (St Louis, MO),
respectively.
EGS and IE mRNA substrate
The DNA sequence coding for EGS IE-SER was generated by
PCR using construct pTK112 (19) as the template with
50 primer oligoIE31 (50-GGAATTCTAATACGACTCACTA-
TAGGTTAACCGGGGTGTGCGGTCTCC-30) and 30 primer
oligoIE32 (50-AAGCTTTAAATGCAACGAGCAGGATTT-
GAACCTGCGCGCG-30). The DNA sequence coding for
IE-C51 was generated by PCR using construct pTKC51 (20)
as the template with 50 primer oligoIE41 (50-GGAATTC-
TAATACGACTCACTATAGGTTAACCGGGGTGTGTC-
GAATGCAG-30) and 30 primer oligoIE42 (50-AAGCTTTA-
AATGCAACGAGCAGGGGTATGAACTGCATTCGA-30).
The DNA sequences coding for EGS IE-SER-C and IE-C51-C
were derived from those for IE-SER and IE-C51, respectively,
and contained point mutations (50-TTC-30 ! AAG) at the
three highly conserved positions in the T-loop of these
EGSs (Figure 1D and F). These EGS DNA sequences were
under the control of the T7 RNA polymerase promoter. The
DNA template for transcription in vitro of RNA substrate ie37
was constructed by annealing the T7 promoter-containing
oligonucleotide OliT7 (50-TAATACGACTCACTATAG-30)
with oligonucleotide sIE1 (50-CGGGATCCTTTCTCGGGG-
TTCTCGTTGCGATTCCCGGTCCTATAGTGAGTCGTA-
TTA-30). RNA substrate ie37 was synthesized in vitro from
the constructed DNA template using T7 RNA polymerase.
Figure 1. SchematicrepresentationofsubstratesforRNaseP.(A)Anaturalsubstrate(ptRNA).(B)AhybridizedcomplexofatargetRNA(e.g.mRNA)andanEGS




blue color. The site of cleavage by RNase P is marked with an arrowhead.
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Human RNase P was prepared from HeLa cellular extracts as
described previously (16,19,20). The EGSs and [
32P]-labeled
ie37 were incubated with human RNase P at 37 C in buffer A
(50 mM Tris, pH 7.4, 100 mM NH4Cl and 10 mM MgCl2).
Cleavage products were separated in denaturing gels and ana-
lyzed with a STORM840 phosphorimager (Molecular
Dynamics, Sunnyvale, CA). Assays to determine kinetic para-
meters were performed under multiple-turnover conditions,
as described previously (20,23). In brief, the cleavage of sub-
strates was assayed in buffer A at various concentrations
of substrates, both above and below the Km for the substrate.
The amount of substrates was in large excess to that of the
enzymes in order to assure that saturation with the substrate
was achieved in the multiple-turnover conditions. Aliquots
were withdrawn from reaction mixtures at regular intervals
and analyzed in polyacrylamide urea gels, and the values of
Km(apparent) and Vmax(apparent) were obtained from Lineweaver–
Burk double-reciprocal plots (20,23).
The procedures to measure the equilibrium dissociation
constants (Kd) of complexes of the EGSs and the substrates
were modiﬁed from Pyle et al. (24). In brief, using a gel-
shift approach, various concentrations of EGSs were prein-
cubated in buffer B (50 mM Tris, pH 7.5, 100 mM NH4Cl,
10 mM MgCl2, 3% glycerol, 0.1% xylene cyanol and 0.1%
bromophenol blue) for 10 min before mixing with an equal
volume of different concentrations of substrate RNA pre-
heated under identical conditions. The samples were incubated
for 10–120 min to allow binding, then loaded on a 5% poly-
acrylamide gel, and run at 10 W. The electrophoresis running
buffer contained 100 mM Tris–HEPES, pH 7.5 and 10 mM
MgCl2 (24). The value of Kd was then extrapolated from a
graph plotting percent of product bound versus EGS concen-
tration (20). The values were the average of three experiments.
Construction of the EGS-expressing cell lines
The DNA sequences coding for the EGSs were subcloned into
retroviral vector LXSN and placed under the control of the U6
RNA promoter (25,26). The protocols to construct EGS-
expressing cell lines were modiﬁed from Miller and Rosman
(25). In brief, the retroviral vector DNAs that contained the
EGS sequence were transfected into amphotropic PA317 cells
using a mammalian transfection kit purchased from Gibco
BRL (Grand Island, NY). After 48 h post transfection, culture
supernatants that contained retroviruses were collected and
used to infect humanU373MG cells. At 48–72 hpostinfection,
neomycin (Gibco BRL, Grand Island, NY) was added to the
culture medium at a ﬁnal concentration of 600 mg/ml. Cells
were subsequently selected in the presence of neomycin for
2 weeks and neomycin-resistant cells were cloned.
Viral infection and preparation of RNA and
protein extracts
The 1 · 10
6 cells were either mock-infected or infected
with HCMV at a multiplicity of infection (MOI) of 0.05–1
in an inoculum of 1.5 ml DMEM supplemented with 1% fetal
calf serum. The inoculum was replaced with DMEM supple-
mented with 10% FBS after 2 h incubation with cells.
The infected cells were incubated for a certain period of
time (as stated in Results) before harvesting for viral
mRNA or protein isolation. To measure the levels of viral
IE transcripts, some of cells were also treated with 100 mg/
ml cycloheximide prior to and during infection. Total cellular
RNA and protein samples were prepared from the cells as
described previously (21).
Studies of the expression of EGS RNAs and viral genes,
and inhibition of viral replication
Northern analyses were used to determine the expression
levels of EGS RNAs and viral mRNAs. The RNA fractions
were separated in 0.8–2.5% agarose gels that contained form-
aldehyde, transferredtoanitrocellulose membrane, hybridized
with the [
32P]-radiolabeled DNA probes that contained the
HCMV or human b-actin DNA sequences, and analyzed
with a STORM840 phosphorimager. The radiolabeled DNA
probes used to detect EGS RNAs, human b-actin mRNA,
HCMV IE 5 kb RNA transcript, IE1 mRNA, IE2 mRNA
and US2 mRNA were synthesized using a random primed
labeling kit (Boehringer Manheim, Indianapolis, IN).
Western analyses were performed to determine the exp-
ression level of viral proteins. The polypeptides from
cell lysates were separated on either 7.5 or 9% [vol/vol]
SDS–polyacrylamide gels cross-linked with N,N00-methyl-
enebisacylamide, transferred electrically to nitrocellulose
membranes, and reacted to the antibodies against HCMV pro-
teins and human actin. The proteins on the membranes were
subsequently stained using a western chemiluminescent
substrate kit (Amersham Inc., Arlington Heights, IL) and
quantiﬁed with a STORM840 phosphorimager. Quantiﬁca-
tion was performed in the linear range of RNA and protein
detection.
To study the EGS-mediated inhibition of viral replication,
5 · 10
5 cells were infected with HCMV at an MOI of 0.5–2.
The cells and medium were harvested at 1 day intervals
throughout 7 days postinfection and viral stocks were prepared
by adding an equal volume of 10% skim milk, followed by
sonication. The titers of the viral stocks were determined by
infecting 1 · 10
5 human foreskin ﬁbroblasts and counting the
number of plaques 10–14 days postinfection. The values
obtained were the average from triplicate experiments.
RESULTS
In vitro studies of targeting activities of the EGS RNAs
IE1 and IE2 are the major transcriptional regulators required
for the expression of viral early (b) and late (g) genes (1). They
share 85 N-terminal amino acids due to alternative splicing
and polyadenylation of transcripts initiating at a strong
promoter–enhancer (27). Therefore, targeting the overlapping
region (e.g. exon 3) of the mRNAs coding for IE1 and IE2
should simultaneously shut down the expression of both pro-
teins and may yield a more effective inhibition of viral rep-
lication. Since most mRNA species inside cells are associated
with proteins and are present in a folded conformation, it is
important to choose a target region that is accessible for EGS
binding in order to achieve efﬁcient targeting. We have used
an in vivo mapping approach with dimethyl sulphate (DMS)
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mRNAs. A position, 146 nt downstream from the 50 terminus
of exon 3, was chosen as the cleavage site for human RNase P.
The targeted region (designated as IE mRNA) is one of the
sequences most accessible to DMS modiﬁcation and is likely
accessible to EGS binding (data not shown).
We have employed previously an in vitro selection proced-
ure to isolate EGS RNA variants that are more efﬁcient in
directing human RNase P for cleavage of the TK mRNA
sequence than the EGS derived from a natural tRNA sequence
(20). However, little is known whether these variants are also
highly active when they are used to target another mRNA.
Whether the EGS RNAs can be used for effective inhibition
of HCMV gene expression and growth has not been reported.
To address these issues, we chose variant C51 for the study
because the EGS RNAs derived from this variant are among
the most active EGSs in inducing RNase P to cleave the TK as
well as the IE1/IE2 mRNA sequences in vitro (see below,
Table 1). By covalently linking the EGS domain of C51 to
the targeting sequences that are complementary to the IE
mRNA, we constructed EGS IE-C51, which resembles a
part of a tRNA structure and contains a T-loop, a T-stem
and a variable region but not the anticodon region that is
dispensable for EGS activity (Figure 1E). Another EGS, IE-
SER, which was derived from the natural tRNA
ser sequence,
was also constructed in a similar way and included in the study
(Figure 1C). The DNA sequences that code for the EGSs and
are driven under the promoter of T7 RNA polymerase were
generated by PCR using primers that contained the sequences
complementary to the targeting region of IE mRNA. EGS
RNAs were synthesized in vitro from these DNA sequences
by T7 RNA polymerase and subsequently incubated with
human RNase P and substrate ie37, which contains an IE
mRNA sequence of 37 nt. IE-SER and IE-C51 efﬁciently
directed human RNase P to cleave IE mRNA sequence
in vitro as apparent cleavage of the substrate was observed
in the presence of these EGSs (Figure 2, lanes 3–4). In con-
trast, no cleavage of ie37 by RNase P was observed in the
absence of these EGSs (Figure 2, lane 1).
Tofurther studythe activityoftheEGSininducingRNaseP
tocleave IEmRNA sequenceinvitro,detailed kineticanalyses
for the reactions in the presence of different EGSs were carried
out, and the values of Km(apparent) and Vmax(apparent) as well as
the overall cleavage efﬁciency [Vmax(apparent)/Km(apparent)] for
the cleavage reactions were determined. These results indicate
that IE-C51 was highly efﬁcient in directing human RNase P
to cleave ie37 and was at least 25-fold more active than IE-
SER (Table 1). An increase in the cleavage rate of RNase P
may be due to additional tertiary interactions that may poten-
tially stabilize the mRNA–EGS complex. If this is the case, it
is expected that binding afﬁnity of the EGS variant (i.e. IE-
C51) to the IE mRNA sequence may be better than that of the
EGS (i.e. IE-SER) derived from the natural tRNA sequence.
The binding afﬁnities of EGS IE-C51 and IE-SER to substrate
ie37, measured as the dissociation constant (Kd), were determ-
ined using gel-shift assays by separating substrate–EGS com-
plexes in polyacrylamide gels under non-denaturing
conditions. IE-C51 exhibited about 30 times higher binding
afﬁnity to ie37 than IE-SER (Table 1). Given the fact that both
IE-C51 and IE-SER have the same antisense sequences (7 and
6 nt, respectively) to ie37 (Figure 1C and E), these results
strongly suggest that the increased binding afﬁnity and the













Ser 0.014 ± 0.003 0.040 ± 0.010 2.9 ± 0.5
IE mRNA (ie37)
+IE-SER 0.60 ± 0.09 0.036 ± 0.015 0.06 ± 0.02 1.2 ± 0.3
+IE-SER-C ND ND <0.001 1.3 ± 0.2
+IE-CSI 0.42 ± 0.08 0.63 ± 0.11 1.5 ± 0.3 0.040 ± 0.006
+IE-CSI-C ND ND <0.001 0.045 ± 0.007
Multiple-turnoverkineticanalysestodeterminethevaluesofVmax(apparent)andKm(apparent)werecarriedoutinbufferA(50mMTris,pH7.4,100mMNH4Cland10mM
MgCl2)a t3 7  C, as described previously (20,23,37). The amounts of substrates were in large excess to that of the enzyme in order to assure that saturation with the
substratewasachievedinthemultiple-turnoverconditions.Todeterminethebindingaffinity(Kd)betweensubstrateie37andEGSs,bindingassayswerecarriedoutin
theabsenceofhumanRNasePinbufferB(50mMTris,pH7.5,100mMNH4Cl,10mMMgCl2,3%glycerol,0.1%xylenecyanoland0.1%bromophenolblue),usinga
protocol modified from Pyle et al. (24). The values shown are the average derived from triplicate experiments.
Figure 2. RNase P-mediated cleavage of ie37 in the presence of different EGS
RNAs. No EGS was included in the reaction mixture in lane 1. An aliquot
of 10 nM (lanes 2 and 3) and 5 nM of the EGS (lane 4) were incubated with
32P-labeled ie37 RNA substrate (10 nM) and either 4 U (lanes 1–3) or 1 U
(lane 4) of human RNase P at 37 C in a volume of 10 ml for 45 min in buffer A
(50 mM Tris, pH 7.0, 100 mM NH4Cl and 10 mM MgCl2). Cleavage products
were separated on 10% polyacrylamide gels that contained 8 M urea.
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introduced by this EGS.
Intracellular expression of EGS RNAs in human
cell culture
The DNA sequences coding for IE-C51 and IE-SER were
subcloned into retroviral vector LXSN and placed under the
control of the small nuclear U6 RNA promoter, which has
been shown previously to express EGS RNA and other
RNAs steadily (16,26,29). This promoter is transcribed by
RNA polymerase III, and its transcripts are highly expressed
and primarily localized in the nucleus (16,26,29).
Two additional EGSs, IE-C51-C and IE-SER-C, were also
constructed and cloned under the control of the U6 RNA
promoter. IE-C51-C and IE-SER-C were derived from IE-
C51 and IE-SER, respectively, and contained point mutations
(50-UUC-30 ! AAG)at the threehighly conserved positions in
the T-loop of these EGSs (Figure 1D and F). These nucleotides
were found in most of the known natural tRNA sequences (30)
and are believed to be important for the interactions between
the tRNA domains and human RNase P (13). Previous studies
have shown that EGSs carrying these mutations precluded
RNase P recognition and exhibited little activity in directing
RNase P-mediated cleavage (20,23,31). Indeed, cleavage of
ie37 by human RNase P in the presence of these two control
EGSs was barely detected (Figure 2, lane 2 and data not
shown) and was at least 1.5 · 10
3-fold slower than the cleav-
age in the presence of IE-C51 (Table 1). IE-C51-C and IE-
SER-C contained the same antisense sequence to the IE
mRNA sequence as IE-C51 and IE-SER (Figure 1D and F),
and exhibited similar binding afﬁnities to ie37 as IE-C51 and
IE-SER, respectively, when assayed in vitro (Table 1). There-
fore, IE-C51-C and IE-SER-C can be used as controls for the
antisense effect of these EGSs.
ToconstructcelllinesthatexpressEGSRNAs,amphotropic
packaging cells (PA317) were transfected with LXSN-EGS
DNAs to produce retroviral vectors that contained the genes
forEGSRNAs.HumanU373MG cells were then infected with
these vectors, and cells expressing the EGSs were cloned. To
determine whether EGS RNA with an incorrect guide
sequence could target the HCMV mRNA in tissue culture,
we also constructed an additional cell line that expressed a
control EGS TK112, which targeted TK mRNA of HSV-1
(19). The TK mRNA is not found in HCMV and, therefore,
is expressed from a promoter different from those of HCMV
IE1 and IE2 (1). No RNase P-mediated cleavage of substrate
ie37 in the presence of TK112 was observed in vitro (data not
shown). The level of EGS RNA expression in each individual
cell clone was determined by northern analysis with DNA
probes that are complementary to the EGSs, using the expres-
sion of human H1 RNA as the internal control (Figure 3).
Figure 3 shows the result from cloned cell lines that ex-
pressed IE-SER, IE-SER-C, IE-C51 and IE-C51-C (lanes
2–5 and 6–10). The constructed lines and a control line in
which cells were transfected with LXSN vector DNA alone
were indistinguishable in terms of their growth and viability
for up to 2 months (data not shown), suggesting that the
expression of the EGSs did not exhibit signiﬁcant cytotoxicity.
Only the cell lines that expressed similar levels of these EGS
RNAs were used for further studies in tissue culture.
Inhibition of HCMV IE1/IE2 expression in
EGS-expressing cells
To determine if the EGSs inhibited IE1 and IE2 expression,
cells were infected with HCMV at a MOI of 0.05–1.
Total RNAs were isolated from cells that were pretreated
with 100 mg/ml of cycloheximide and then were either
mock-infected or infected with HCMV. Under this condition,
only viral IE mRNAs would be synthesized (1). The levels of
IE1/IE2 mRNAs in the infected cells were determined by
northern analyses. The level of the 5 kb long viral
immediate-early transcript (5 kb RNA), which expression is
not regulated by IE1/IE2 under the assay conditions (1,32),
was used as an internal control for the quantiﬁcation of expres-
sion of IE1 and IE2 mRNAs. Figure 4 shows the results (which
are summarized in Table 2) of the northern analysis experi-
mentswith theIE1 (Figure 4B),IE2 (Figure 4C) and5kbRNA
probes (Figure 4A). A reduction of  93 and 79% (average of
three experiments) in the levels of IE1 and IE2 mRNA expres-
sion was observed in cells that expressed EGS IE-C51
and IE-SER, respectively (Figure 4, lanes 8–9 and 13–14).
In contrast, cells that expressed IE-C51-C and IE-SER-C
RNAs only exhibited a reduction of <10% (Figure 4, lanes
7 and 12) (Table 2). The low level of inhibition found in cells
that expressed IE-C51-C and IE-SER-C RNAs was prob-
ably due to an antisense effect. This is because IE-C51-C
and IE-SER-C, with the point mutations at the T-loop
(Figure 1D and F), exhibited little targeting activity but
bound to IE mRNA sequence as well as IE-C51 and
IE-SER (Table 1). Thus, these observations suggest that the
signiﬁcant reduction of IE1 and IE2 mRNA expression in
cells that expressed IE-C51 and IE-SER was due to the
Figure 3. (A and B) Northern analyses of the expression of EGS RNAs from
nuclearRNA fractionsisolatedfromparentalU373MGcells (dash, lanes1 and
6)oraclonedcelllinethatexpressedIE-SER(lanes2and7),IE-SER-C(lanes3
and8),IE-C51(lanes4and9)andIE-C51-C(lanes5and10).Equalamountsof
each RNA sample (25 mg) were separated on 2% agarose gels that contained
formaldehyde, transferred on to nitrocellulose membranes, and hybridized to
32P-radiolabeled probes that contained the DNA sequence coding for IE-SER
and IE-C51 (lanes 1–5) or H1 RNA (lanes 6–10), the RNA subunit of human
RNasePandanuclearRNA(13).Thehybridizedproductscorrespondingtothe
full-length retroviral transcripts ( 6 kb), transcribed from the LTR promoter,
are at the top of the gel and are not shown.
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these EGSs. No products of the cleavage of IE1 and IE2
mRNAs were detected in our northern analyses presumably
because these RNAs, which lacked either a cap structure or a
polyA sequence, were rapidly degraded by intracellular
RNases.
The levels of IE1 and IE2 proteins in the EGS-expressing
cells are expected to reduce because of the decreased level of
IE1/IE2 mRNAs. Proteins were isolated from cells at 24 h
postinfection, separated in SDS–polyacrylamide gels, and
transferred to two identical membranes. One membrane was
stained with an anti-IE1/IE2 antibody (anti-IE1/IE2)
(Figure 5B) and the other was stained with a monoclonal
antibody against human actin (anti-Actin) (Figure 5A). The
latter serves as an internal control for the quantiﬁcation of IE1/
IE2 protein expression. The results of three independent
experiments are summarized in Table 2: a reduction of  93
and 78% in the level of IE1 and IE2 proteins was observed in
cells that expressed IE-C51 and IE-SER, respectively, while
a reduction of <10% was found in cells that expressed IE-
C51-C, IE-SER-C or TK112.
InhibitionofHCMVoverallgeneexpressionandgrowth
in the EGS-expression cells
A reduction of IE1 and IE2 expression is expected to result
inaninhibitionoftheexpressionofbothviralearly(b)andlate
(g) genes (1). To determine whether this was the case, cells
were infected with HCMV for 48–72 h. The levels of the US2
mRNA (an early mRNA) (Figure 4D) as well as the protein
levels of UL44 (an early and late protein) and gH (a late
protein) (Figure 5C–D) were determined. The level of the
HCMV 5 kb transcript and the protein level of human actin
were used as the internal controls.
A reduction of  90–92% and 73–75% in the expression
levels of these genes was observed in cells that expressed
IE-C51 and IE-SER RNA, respectively. No signiﬁcant reduc-
tion was detected in cells that expressed IE-C51-C and
IE-SER-C (Figures 4 and 5 and Table 2). Similar results
were also observed in the study of the expression of UL99,
a viral late protein (Table 2 and data not shown). These results
suggest an overall inhibition of viral early and late gene
expression in the cells that expressed IE-C51 and IE-SER.
Table 2. Levels of inhibition of viral gene expression in the cells that expressed EGSs IE-C51, IE-C51-C, IE-SER, IE-SER-C and TK112, as compared with
that in the parental U373MG cells that did not express an EGS (U373MG)
Viral gene class EGS RNA
U373-MG (%) TK112 (%) IE-SER-C (%) IE-C51-C (%) IE-SER (%) IE-C51 (%)
IE1 mRNA a 0 1 6 7 80 ± 6 94 ± 6
IE2 mRNA a 0 2 5 6 79 ± 7 93 ± 5
US2 mRNA b 0 1 1 1 75 ± 6 92 ± 7
IE1/IE2 protein a 0 2 5 6 78 ± 8 93 ± 6
UL44 protein b, g 0 1 2 1 74 ± 6 90 ± 5
gH g 0 0 1 1 73 ± 6 91 ± 5
UL99 g 0 2 1 1 75 ± 6 91 ± 6
The values shown are the means from triplicate experiments and the values of SD that were <5% are not shown.
Figure 4. Levels of HCMV mRNAs as determined by northern analysis. Cells (1 · 10
6) were either mock-infected (lanes 5, 10, 15 and 20) or infected with
HCMV (MOI ¼ 1) (lanes 1–4, 6–9, 11–14 and 16–19) and were harvested at either 8 (A–C)o r2 4h( D) postinfection. Viral infection was carried out either
intheabsence(D)orpresence(A–C)of100mg/mlcycloheximide.NorthernanalyseswerecarriedoutusingRNAsisolatedfromparentalU373MGcells(dash,lanes
1, 5, 6, 10, 11, 15, 16 and 20) and cell lines that expressed IE-SER-C (lanes 2, 7, 12 and 17), IE-SER (lanes 3, 8, 13 and 18) and IE-C51 (lanes 4, 9, 14 and 19).
Equal amounts of each RNA sample (35 mg) were separated on agarose gels that contained formaldehyde, transferred on to a nitrocellulose membrane, and
hybridized to a
32P-radiolabeled probe that contained the cDNA sequence of the HCMV 5 kb transcript (lanes 1–5), IE1 mRNA (lanes 6–10), IE2 mRNA
(lanes 11–15) and US2 mRNA (lanes 16–20). The hybridized products corresponding to the 5 kb RNA, IE1, IE2 and US2 mRNAs were  5, 1.9, 2.2 and
1.5 kb, respectively (1).
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EGS-expressing cells, cells were infected with HCMV at an
MOI of 0.5–2. Virus stocks were prepared from the infected
cultures at 1 day intervals through 7 days postinfection and the
plaque forming unit (PFU) count was determined by measur-
ing the viral titer in human foreskin ﬁbroblasts. After 5 days
postinfection, a reduction of  3000- and 150-fold in viral
yield was observed in cells that expressed IE-C51 and IE-
SER, respectively (Figure 6). No signiﬁcant reduction was
found in those that expressed the control EGSs IE-C51-C,
IE-SER-C or TK112 (Figure 6 and data not shown).
DISCUSSION
RNase P is one of the most ubiquitous and essential enzymes
found in nature as it is responsible for processing of all tRNA
molecules, which accounts for 2% of total RNA species within
a single cell (12,13). The EGS-based technology represents
an attractive approach for gene inactivation since it utilizes
endogenous RNase P tos generate highly efﬁcient and speciﬁc
cleavage of the target RNA. Moreover, RNase P-mediated
cleavage directed by EGSs is speciﬁc and does not generate
‘irrelevant cleavage’, which is usually observed with RNase
H-mediated cleavage induced by conventional antisense
phosphothioate oligonucleotides (13,33). In order to develop
the EGS technology for practical gene-targeting applications,
further studies are needed to study how to improve the efﬁcacy
of the EGSs in inhibiting gene expression.
Littleisknownaboutthe rate-limitingstepofEGS-targeting
reaction in cultured cells. Equally unclear is whether the efﬁ-
cacy of the EGSs can be improved, and if so, how it can be
improved. In the present study, EGS RNAs were constructed
to target an accessible region of IE1 and IE2 mRNAs. More-
over, EGSs were expressed by the small nuclear U6 RNA
promoter. This design would increase the probability
for the EGS RNAs to bind to their target mRNA sequence
and co-localize with human RNase P, which is exclusively
localized in the nuclei (13). Under the described settings, we
hypothesized that the efﬁcacy of EGS technology in cultured
cells is dictated by the catalytic efﬁciency (Vmax/Km) of RNase
P-mediated cleavage directed by the EGS. If this is the case,
increasing the activity of EGS in directing RNase P cleavage
may lead to more effective inhibition of the target mRNA
expression in vivo.
Our results showed that an EGS variant, IE-C51, is about 25
times more active [Vmax(apparent)/Km(apparent)] in directing
RNase P to cleave IE mRNA sequence in vitro than the
EGS (i.e. IE-SER) derived from the natural tRNA
ser sequence.
Moreover, IE-C51 inhibited IE1/IE2 expression in cultured
Figure 5. LevelsofhumanactinandHCMVproteinsasdeterminedbywesternblotanalysis.ProteinsampleswereisolatedfromcellsthatexpressedspecifiedEGSs




Figure 6. Growth analysis of HCMV in parental U373MG cells and cell lines
that expressed IE-C51, IE-SER and IE-SER-C. Cells (1 · 10
5) were infected
with HCMV at an MOI of 1. Virus stocks were prepared from the infected
cells at 1 day intervals through 7 days postinfection and the PFU count was
determined by the measurement of the viral titer on human fibroblasts. These
values are the means from triplicate experiments. SD is indicated by the
error bars.
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reduced IE1/IE2 expression by  80%. A reduction of  3000-
fold in viral growth was observed in the IE-C51-expressing
cells while a reduction of  150-fold was observed in cells
that expressed IE-SER. In contrast, a reduction of <10% in the
IE1/IE2 expression level and viral growth was observed
in cells that expressed IE-C51-C, IE-SER-C or TK112.
IE-C51-C and IE-SER-C exhibited similar binding afﬁnity
to ie37 as IE-C51 and IE-SER, respectively, but were inactive
in directing RNase P-mediated cleavage due to the presence of
themutationsattheT-loopthatprecludedRNasePrecognition
(Figures 1 and 2 and Table 1). These results suggest that the
observed reduction in viral gene expression and inhibition
ofviral growth with IE-C51 and IE-SER isprimarily attributed
to the speciﬁc targeted RNase P-mediated cleavage induced
by these two EGSs as opposed to the antisense effect or other
nonspeciﬁc effects of the EGSs. Moreover, the EGS (i.e.
IE-C51) that is more active [Vmax(apparent)/Km(apparent)] in indu-
cing RNase P to cleave IE mRNA sequence in vitro is also
more effective in inhibiting HCMV gene expression and
growth in cultured cells. These results strongly support our
hypothesis that increasing the activity of EGS in directing
RNase P cleavage may lead to improved efﬁcacy in inhibiting
gene expression in cultured cells. The difference between the
in vivo efﬁcacies of IE-C51 and IE-SER (e.g. 92 versus 80%)
appeared to be more limited than that of the in vitro cleavage
efﬁciencies ( 25-fold difference). One of the possible
explanations is that about 5–10% of the target mRNA
may not be accessible to EGS binding or RNase P cleavage,
possibly due to its speciﬁc nuclear localization and its rapid
transport to the cytoplasm.
HCMV, like all human herpesviruses, expresses its mRNAs
and replicates its genome in the nuclei (1). Indeed, the viral
transcription and replication occurs at speciﬁc compart-
ments within the nuclei, possibly including the nucleolus. It
is also shown that HCMV transcription and replication may
result in changes of certain nuclear structures (1). RNase P is
localized in the nucleolus (13). Furthermore, transcripts
expressed from the U6 RNA promoter, such as the EGSs in
our study, are expected to be expressed in the nuclei, and
possibly primarily in the nucleolus (16,26,29). Our results
indicate that EGSs and RNase P can effectively target
HCMV IE1/IE2 mRNAs in nuclear compartments, although
the exact location for synthesis of IE1/IE2 mRNAs in
the nucleus or whether it is in the nucleolus is currently
unknown.
Several lines of evidence presented in our study indicate
that the EGS is highly speciﬁc. First, the presence of EGSs
did not exhibit signiﬁcant cytotoxicity as cells expressing
EGSs are indistinguishable from the parental cells in terms
of cell growth and viability for up to 2 months (data not
shown). Moreover, the antiviral effect associated with the
expression of IE-C51 and IE-SER RNAs (inhibition of viral
growth) appears to be due to the reduction of IE1 and IE2
expression. This is because the expression of all the viral early
and late genes examined, including US2, UL44, gH and UL99,
was found to be signiﬁcantly reduced in cells that expressed
IE-C51 and IE-SER but not in those that expressed IE-C51-C,
IE-SER-C and TK112 (Figures 4and 5,Table 2). The extentof
the observed inhibition of the expression of most of these viral
early and late genes correlates with that of the inhibition of the
IE1 and IE2 expression. Meanwhile, no reduction in the levels
of other viral IE transcripts (e.g. 5 kb RNA and UL36 mRNA)
was detected in the EGS-expressing cells (Figure 4A and data
not shown). Thus, EGS is highly speciﬁc in inhibiting the
expression of its target mRNA.
Our results suggest that the enhanced stability of the
mRNA–EGS complexes may possibly contribute to the
increased targeting activity of EGS IE-C51. IE-C51 bound
to substrate ie37 at least 25-fold better than IE-SER
(Table 1). Previous studies on tRNA molecules indicated
that tertiary interactions between variable region and
D-loop are important for maintaining the tRNA conformation
and RNase P cleavage (12,13). Given the fact that, in the
ie37–IE-C51 complex, the 30 region of ie37 can be considered
equivalent to the D-loop in a tRNA (Figure 1E), it is con-
ceivable that the additional interactions between ie37 and
IE-C51 stabilize the mRNA–EGS complex and result in an
enhanced binding afﬁnity and increased targeting activity of
the EGS.
In vitro selection has been widely used to generate highly
active ribozymes and functional RNA molecules that have
increased activity (34–36). Furthermore, this procedure has
been used to generate novel RNA molecules that can serve
as the substrates for RNase P and its catalytic RNA subunits
(23,37,38). In vitro selection was also used to generate EGS
molecules that direct human RNase P to cleave the mRNA
encoding chloramphenicol acetyltransferase (CAT) (23).
However, whether these selected EGSs exhibit higher efﬁca-
cies in targeting CAT mRNA in tissue culture has not yet been
extensively studied. Using an EGS RNA variant selected from
a pool of EGS molecules containing randomized sequences,
we, in this study, provide direct evidence that an EGS selected
in vitro with increased targeting activity also exhibited
improved efﬁcacy in inhibiting HCMV gene expression and
growth in cultured cells. Thus, our study provides a direction
for the engineering and generation of highly active and effect-
ive EGS molecules by carrying out selection procedures and
manipulation of the EGS domain to interact with the mRNA
substrates. Further characterization of the cleavage reactions
of this as well as other EGS variants both in vitro and in
cultured cells should provide insights into the mechanism
of how an EGS RNA efﬁciently directs RNase P to cleave
an mRNA substrate and develop guidelines for construction of
effective gene-targeting EGSs.
HCMV, a member of the human herpesvirus family that
includes seven other different viruses such as HSV and
Epstein–Barr virus, can engage in lytic replication as well
as establish latent infections (1,39,40). HCMV IE1 and IE2
are among the ﬁrst viral proteins expressed during lytic infec-
tion. Their homologous proteins have been found in every
other herpesviruses and are among those that are major targets
for drug development. To further evaluate the anti-HCMV
activity of EGS RNA, the EGSs can be delivered into the
monocyte/macrophage-lineage cells where HCMV is believed
to establish latent infections (1). These experiments will deter-
mine whether the EGSs can abolish the IE1/IE2 expression in
these cells and prevent HCMV reactivation from latent infec-
tion into lytic replication. These studies, as well as the in vitro
studies on how to construct highly active EGSs, will facilitate
the development of EGSs as exciting novel gene-targeting
agents for antiviral applications.
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